27 unknown. 27 Phase 2, 11 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Unknown 27 |
| Phase 1 | 11 | Unknown 11 |
| Phase 3 | 4 | Unknown 4 |
Follow Acute Lymphoblastic Leukemia: new trials by email Literature Review of Acute Lymphoblastic Leukemia trials Research Report on Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT VEN+AZA+Modified BUCY - Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 55 | 2022-01-20 | 2023-04-12 |
| Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL Cladribine, Fludarabine - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 32 | 2022-01-01 | 2022-10-13 |
| Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL PTG-CARCIK-CD19 - Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 35 | 2021-12-01 | 2023-05-06 |
| A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL Navitoclax, Venetoclax - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Israeli Medical Association | 48 | 2021-10-01 | 2021-09-23 |
| Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT Ex-vivo expanded γδ T cell infusion - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 20 | 2021-09-12 | 2022-03-28 |
| Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL Car-T Cell Therapy - Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Acibadem University | 24 | 2019-10-12 | 2020-01-27 |
| Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test - Acute Myeloid Leukemia in Remission, Lymphoma in Remission | Phase 2 / Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 227 | 2019-09-16 | 2021-09-28 |
| CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients CD19 hsCAR-T - Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Xuanwu Hospital, Beijing | 50 | 2019-04-22 | 2019-04-08 |
| CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology - Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 / Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 40 | 2017-07-01 | 2024-05-28 |
| D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia Dasatinib, Blinatumomab - Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 60 | 2017-05-31 | 2018-03-22 |
| CART-19 Cells For MRD Positive CD19+ ALL CART-19 - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Unknown | Fujian Medical University | 20 | 2016-11-01 | 2017-01-23 |
| Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies Second generation CAR-T cells, Hematological stem cell transplantation - Acute Lymphoblastic Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Wuhan Sian Medical Technology Co., Ltd | 20 | 2016-05-01 | 2018-11-20 |
| Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies Allogeneic hematological stem cell transplantation - Acute Lymphoblastic Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Wuhan Sian Medical Technology Co., Ltd | 50 | 2016-04-15 | 2019-05-10 |
| Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia Cladribine, G-CSF, Cytarabine - Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Sun Yat-sen University | 50 | 2016-01-01 | 2019-08-20 |
| CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies Second generation CAR-T cells - Acute Lymphoblastic Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Wuhan Sian Medical Technology Co., Ltd | 80 | 2015-12-02 | 2019-05-10 |
| Study of Palbociclib in MLL-rearranged Acute Leukemias Palbociclib - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | University of Ulm | 50 | 2015-07-01 | 2019-04-16 |
| Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction Pentoxifylline Plus Chemotherapy, Placebo Plus Chemotherapy - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Unknown | Ramón Óscar González-Ramella, Ph.D | 44 | 2015-01-01 | 2018-05-09 |
| Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children high dose methotrexate, Intrathecal triple chemotherapy - Acute Lymphoblastic Leukemia, Child | Phase 2 | Unknown | The Korean Society of Pediatric Hematology Oncology | 110 | 2015-01-01 | 2015-01-16 |
| Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL. Busulfan - Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Seoul National University Hospital | 38 | 2014-02-05 | 2023-02-06 |
Showing 20 of 27. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (27) · Leukemia, Myeloid, Acute (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Myelodysplastic Syndromes (3) · Lymphoma (2) · Recurrence (2) · Anemia, Aplastic (1) · Burkitt Lymphoma (1) · Central Nervous System Diseases (1) · Hodgkin Disease (1) · Multiple Myeloma (1) · Neoplasms (1)
Hematologic Diseases (27) · Hemic and Lymphatic Diseases (27) · Immune System Diseases (27) · Immunoproliferative Disorders (27) · Leukemia (27) · Leukemia, Lymphoid (27) · Lymphatic Diseases (27) · Lymphoproliferative Disorders (27) · Neoplasms by Histologic Type (27) · Neoplasms (26) · Lymphoma (6) · Disease Attributes (5) · Leukemia, Myeloid (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Cladribine (3) · Cytarabine (3) · Drug Therapy (2) · Granulocyte Colony-Stimulating Factor (2) · Immunotherapy, Adoptive (2) · Methotrexate (2) · venetoclax (2) · ANAVACYM protocol (1) · Anthracyclines (1) · Busulfan (1) · CTL019 chimeric antigen receptor (1) · Dasatinib (1) · Inotuzumab Ozogamicin (1) · Mitoxantrone (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1)
Wuhan Sian Medical Technology Co., Ltd (3) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · The First Affiliated Hospital of Soochow University (2) · Acibadem University (1) · Assistance Publique - Hôpitaux de Paris (1) · Chinese PLA General Hospital (1) · Colorado Blood Cancer Institute (1) · Cooperative Study Group A for Hematology (1) · Fondazione Matilde Tettamanti Menotti De Marchi Onlus (1) · Fujian Medical University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Israeli Medical Association (1) · Nantes University Hospital (1) · National Cancer Institute, Naples (1) · New York Medical College (1)
China (10) · Germany (3) · Italy (3) · South Korea (3) · France (2) · United States (2) · Belgium (1) · Israel (1) · Mexico (1) · Turkey (Türkiye) (1)
YU HU, M.D., Ph.D (2) · A. Pession (1) · Chevallier Patrice, MD (1) · Chunji Gao, Professor (1) · Depei Wu Wu, MD (1) · E. Strocchi (1) · Ercument Ovali, MD (1) · Francesco Perrone, M.D., Ph.D. (1) · Franco Mandelli, Prof. (1) · Huyong Zheng, MD, PhD (1) · Hyoung Jin Kang, MD, PhD (1) · Jianda Hu, 86-13959169016 (1) · Julia Winkler, MD (1) · Jung-Hee Lee, Doctor (1) · Karen Seiter, MD (1)
PMID 40195173, PMID 11675328, PMID 16155013, PMID 17366834, PMID 18358930, PMID 21220611, PMID 21846410, PMID 21943236, PMID 22037714, PMID 22074157, PMID 22086414, PMID 22265847, PMID 22323480, PMID 23140366, PMID 23244073, PMID 26687796, PMID 33085860, PMID 33235353, PMID 33593877, PMID 34048072, PMID 35799791, PMID 36105799, PMID 38127722, PMID 38467031, PMID 39421449